Efficacy and safety of lemborexant in subjects with insomnia disorder receiving medications for depression or anxiety symptoms

Documenti analoghi

• Associations Between Cognitive Impairment, Depressive Symptoms, and Work Productivity Loss in Patients With Bipolar Disorder: A Cross‐Sectional Analysis
  di: Yoshikazu Takaesu, et al.
  Pubblicazione: (2025)
• Successful treatment with guanfacine in a long‐COVID case manifesting marked cognitive impairment
  di: Tsuyoshi Kondo, et al.
  Pubblicazione: (2024)
• A psychometric analysis of the Japanese version of the clinically useful depression outcome scale supplemented with questions for the DSM‐5 anxious distress specifier (CUDOS‐A)
  di: Yumi Aoki, et al.
  Pubblicazione: (2024)
• Investigation of risk factors associated with the development of depressive symptoms in healthy subjects exposed to long‐term stress: A prospective study of the Japanese Antarctic research expedition wintering party
  di: Takashi Fukunishi, et al.
  Pubblicazione: (2024)
• Factor structure and psychometric properties of the Jordanian version of the depression anxiety stress scale (DASS‐21)
  di: Khaled A. Al‐Dassean, et al.
  Pubblicazione: (2024)